Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 23
Filtrar
Mais filtros

Base de dados
País/Região como assunto
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
Int J Mol Sci ; 25(5)2024 Feb 27.
Artigo em Inglês | MEDLINE | ID: mdl-38473983

RESUMO

Asians have a higher carrier rate of pulmonary arterial hypertension (PAH)-related genetic variants than Caucasians do. This study aimed to identify PAH-related genetic variants using whole exome sequencing (WES) in Asian idiopathic and heritable PAH cohorts. A WES library was constructed, and candidate variants were further validated by polymerase chain reaction and Sanger sequencing in the PAH cohort. In a total of 69 patients, the highest incidence of variants was found in the BMPR2, ATP13A3, and GDF2 genes. Regarding the BMPR2 gene variants, there were two nonsense variants (c.994C>T, p. Arg332*; c.1750C>T, p. Arg584*), one missense variant (c.1478C>T, p. Thr493Ile), and one novel in-frame deletion variant (c.877_888del, p. Leu293_Ser296del). Regarding the GDF2 variants, there was one likely pathogenic nonsense variant (c.259C>T, p. Gln87*) and two missense variants (c.1207G>A, p. Val403Ile; c.38T>C, p. Leu13Pro). The BMPR2 and GDF2 variant subgroups had worse hemodynamics. Moreover, the GDF2 variant patients were younger and had a significantly lower GDF2 value (135.6 ± 36.2 pg/mL, p = 0.002) in comparison to the value in the non-BMPR2/non-GDF2 mutant group (267.8 ± 185.8 pg/mL). The BMPR2 variant carriers had worse hemodynamics compared to the patients with the non-BMPR2/non-GDF2 mutant group. Moreover, there was a significantly lower GDF2 value in the GDF2 variant carriers compared to the control group. GDF2 may be a protective or corrected modifier in certain genetic backgrounds.


Assuntos
Hipertensão Arterial Pulmonar , Humanos , Hipertensão Arterial Pulmonar/genética , Hipertensão Pulmonar Primária Familiar/genética , Mutação de Sentido Incorreto , Hemodinâmica , Deleção de Sequência , Receptores de Proteínas Morfogenéticas Ósseas Tipo II/genética , Mutação , Adenosina Trifosfatases/genética , Proteínas de Membrana Transportadoras/genética , Fator 2 de Diferenciação de Crescimento/genética
2.
J Hum Genet ; 65(7): 619-625, 2020 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-32246049

RESUMO

The Fabry disease-causing mutation, the GLA IVS4+919G>A (designated GLA IVS4), is very prevalent in patients with hypertrophic cardiomyopathy in Taiwan. This X-linked mutation has also been found in patients in Kyushu, Japan and Southeast Asia. To investigate the age and the possible ancestral origin of this mutation, a total of 33 male patients with the GLA IVS4+919G>A mutation, born in Taiwan, Japan, Singapore, Malaysia, Vietnam, and the Fujian and Guangdong provinces of China, were studied. Peripheral bloods were collected, and the Ilumina Infinium CoreExome-24 microarray was used for dense genotyping. A mutation-carrying haplotype was discovered which was shared by all 33 patients. This haplotype does not exist in 15 healthy persons without the mutation. Rather, a wide diversity of haplotypes was found in the vicinity of the mutation site, supporting the existence of a single founder of the GLA IVS4 mutation. The age of the founder mutation was estimated by the lengths of the mutation-carrying haplotypes based on the linkage-disequilibrium decay theory. The first, second, and third quartile of the age estimates are 800.7, 922.6, and 1068.4 years, respectively. We concluded that the GLA IVS4+919G>A mutation originated from a single mutational event that occurred in a Chinese chromosome more than 800 years ago.


Assuntos
Cardiomiopatia Hipertrófica Familiar/genética , Doença de Fabry/genética , alfa-Galactosidase/genética , Adulto , Cardiomiopatia Hipertrófica Familiar/epidemiologia , Cardiomiopatia Hipertrófica Familiar/patologia , China/epidemiologia , Doença de Fabry/epidemiologia , Doença de Fabry/patologia , Genes Ligados ao Cromossomo X/genética , Genótipo , Haplótipos/genética , Humanos , Japão/epidemiologia , Malásia/epidemiologia , Masculino , Pessoa de Meia-Idade , Mutação/genética , Taiwan/epidemiologia
3.
Genet Med ; 21(1): 224-232, 2019 01.
Artigo em Inglês | MEDLINE | ID: mdl-29875425

RESUMO

PURPOSE: Evaluation standards and treatment initiation timing have been debated for a long time, particularly for late-onset Fabry disease (FD), because of its slow progression. However, early initiation of enzyme replacement therapy (ERT) for FD could be effective in stabilizing the disease progression and potentially preventing irreversible organ damage. We aimed to examine globotriaosylceramide (Gb3) deposits in patients' endomyocardial biopsies to understand the early pathogenesis of FD cardiomyopathy. METHODS: Immunofluorescent (IF) staining of Gb3 and lysosomal-associated membrane protein 1 (LAMP-1) was performed on endomyocardial biopsies of patients suspected of Fabry cardiomyopathy who had negative or only slight Gb3 accumulation determined by toluidine blue staining and electron microscopic examination. RESULTS: The IF staining results revealed that all patients examined had abundant Gb3 accumulation in their cardiomyocytes, including the ones who are negative for inclusion bodies. Furthermore, we found that early Gb3 deposits were mostly confined within lysosomes, while they appeared extralysosomally at a later stage. CONCLUSION: A significant amount of lysosomal Gb3 deposits could be detected by IF staining in cardiac tissue before the formation of inclusion bodies, suggesting the cardiomyocytes might have been experiencing cellular stress and damage early on, before the appearance of typical pathological changes of FD during the disease progression.


Assuntos
Doença de Fabry/diagnóstico , Globosídeos/metabolismo , Lisossomos/metabolismo , Miocárdio/metabolismo , Triexosilceramidas/metabolismo , Adulto , Biópsia , Progressão da Doença , Terapia de Reposição de Enzimas , Doença de Fabry/diagnóstico por imagem , Doença de Fabry/metabolismo , Doença de Fabry/patologia , Imunofluorescência , Globosídeos/genética , Humanos , Proteínas de Membrana Lisossomal/genética , Lisossomos/patologia , Masculino , Pessoa de Meia-Idade , Miocárdio/patologia , Triexosilceramidas/genética
4.
J Hum Genet ; 63(1): 1-8, 2018 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-29215092

RESUMO

Many female carriers of Fabry disease are likely to develop severe morbidity and mortality. However, by our own estimation, around 80% of female newborns are missed by our current enzyme-based screening approach. Our team's aim was to develop an improved cost-effective screening method that is able to detect Fabry disease among female newborns. In Taiwan, based on a database of 916,000 newborns, ~98% of Fabry patients carry mutations out of a pool of only 21 pathogenic mutations. An Agena iPLEX platform was designed to detect these 21 pathogenic mutations using only a single-assay panel. A total of 54,791 female infants were screened and 136 female newborns with the IVS4 + 919G > A mutation and one female newborn with the c.656T > C mutation were identified. Using the current enzyme-based newborn screening approach as baseline, around 83% of female newborns are being missed. Through a family study of the IVS4 female newborns, 30 IVS4 adult family members were found to have left ventricular hypertrophy. Ten patients received endomyocardial biopsy and all were found to have significant globotriaosylceramide (Gb3) accumulation in their cardiomyocytes. All of these individuals now receive enzyme replacement therapy. We have demonstrated that the Agena iPLEX assay is a powerful tool for detecting females with Fabry disease. Furthermore, through this screening, we also have been able to identify many disease-onset adult family members who were originally undiagnosed for Fabry disease. This screening helps them to receive treatment in time before severe and irreversible cardiac damage has occurred.


Assuntos
DNA/análise , Doença de Fabry/diagnóstico , Programas de Rastreamento , Espectrometria de Massas , Adulto , Feminino , Humanos , Recém-Nascido , Programas de Rastreamento/instrumentação , Programas de Rastreamento/métodos , Espectrometria de Massas/instrumentação , Espectrometria de Massas/métodos , Sensibilidade e Especificidade
5.
Rheumatol Int ; 34(5): 625-9, 2014 May.
Artigo em Inglês | MEDLINE | ID: mdl-24178067

RESUMO

Growth arrest-specific protein 6 (Gas6) is a serum protein involved in granulocyte, platelet and endothelium interaction, and is implicated in both anti-inflammatory response as well as platelet/leukocytes activation. We investigated serum Gas6 level in different clinical manifestations of systemic lupus erythematosus (SLE). Data were collected in 83 patients with SLE and 40 non-lupus controls. The Gas6 levels were detected by enzyme-linked immunosorbent assay. Our results demonstrated that the Gas6 level was higher in SLE patients as compared to the non-lupus control subjects (SLE vs. non-lupus control, median [inter-quartile range (IQR)] 22.67 [19.40-28.60] vs. 18.97 [16.05-20.62] ng/mL, p < 0.01). Furthermore, Gas6 level was higher in patients with nephritis (nephritis vs. non-nephritis, median [IQR] 26.21 [21.17-31.61] vs. 22.22 [18.98-26.98] ng/mL, p = 0.03) and in patients with cutaneous vasculitis (vasculitis vs. non-vasculitis, median [IQR] 27.89 [23.24-34.26] vs. 22.30 [19.32-27.16] ng/mL, p = 0.03). Our results indicate that the serum Gas6 level is increased in SLE patients with lupus nephritis or cutaneous vasculitis, implicating a potential to serve as a SLE disease activity marker.


Assuntos
Peptídeos e Proteínas de Sinalização Intercelular/sangue , Lúpus Eritematoso Sistêmico/sangue , Nefrite Lúpica/sangue , Vasculite/sangue , Adulto , Biomarcadores/sangue , Estudos de Casos e Controles , Progressão da Doença , Feminino , Humanos , Lúpus Eritematoso Sistêmico/diagnóstico , Nefrite Lúpica/diagnóstico , Masculino , Pessoa de Meia-Idade , Prognóstico , Regulação para Cima , Vasculite/diagnóstico
6.
JACS Au ; 4(3): 908-918, 2024 Mar 25.
Artigo em Inglês | MEDLINE | ID: mdl-38559739

RESUMO

The use of pharmacological chaperones (PCs) to stabilize specific enzymes and impart a therapeutic benefit is an emerging strategy in drug discovery. However, designing molecules that can bind optimally to their targets at physiological pH remains a major challenge. Our previous study found that dibasic polyhydroxylated pyrrolidine 5 exhibited superior pH-selective inhibitory activity and chaperoning activity for human α-galactosidase A (α-Gal A) compared with its monobasic parent molecule, 4. To further investigate the role of different C-2 moieties on the pH-selectivity and protecting effects of these compounds, we designed and synthesized a library of monobasic and dibasic iminosugars, screened them for α-Gal A-stabilizing activity using thermal shift and heat-induced denaturation assays, and characterized the mechanistic basis for this stabilization using X-ray crystallography and binding assays. We noted that the dibasic iminosugars 5 and 20 protect α-Gal A from denaturation and inactivation at lower concentrations than monobasic or other N-substituted derivatives; a finding attributed to the nitrogen on the C-2 methylene of 5 and 20, which forms the bifurcated salt bridges (BSBs) with two carboxyl residues, E203 and D231. Additionally, the formation of BSBs at pH 7.0 and the electrostatic repulsion between the vicinal ammonium cations of dibasic iminosugars at pH 4.5 are responsible for their pH-selective binding to α-Gal A. Moreover, compounds 5 and 20 demonstrated promising results in improving enzyme replacement therapy and exhibited significant chaperoning effects in Fabry cells. These findings suggest amino-iminosugars 5 and 20 as useful models to demonstrate how an additional exocyclic amino group can improve their pH-selectivity and protecting effects, providing new insights for the design of pH-selective PCs.

7.
Phys Rev E ; 107(6-2): 065105, 2023 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-37464647

RESUMO

The effect of wing shape on a forward-flying butterfly via decoupled factors of the wing-swept angle and the aspect ratio (AR) was investigated numerically. The wing-shape effect is a major concern in the design of a microaerial vehicle (MAV). In nature, the wing of a butterfly consists of partially overlapping forewing and hindwing; when the forewing sweeps forward or backward relative to the hindwing, the wing-swept angle and the AR of the entire wing simultaneously change. The effects of the wing-swept angle and AR on aerodynamics are coupled. To decouple their effects, we established wing-shape models with varied combinations of the wing-swept angle and AR based on the experimental measurement of two butterfly species (Papilio polytes and Kallima inachus) and developed a numerical simulation for analysis. In each model, the forewing and hindwing overlapped partially, constructing a single wing. Across the models, the wing-swept angle and AR of these single wings varied sequentially. The results show that, through our models, the effects of the wing-swept angle and AR were decoupled; both have distinct flow mechanisms and aerodynamic force trends and are consistent in the two butterfly species. For a fixed AR, a backward-swept wing increases lift and drag because of the enhanced attachment of the leading-edge vortex with increased strength of the wingtip vortex and the spanwise flow. For a fixed wing-swept angle, a small AR wing increases lift and decreases drag because of the large region of low pressure downstream and the wake-capture effect. Coupling these effects, the largest lift-to-drag ratio occurs for a forward-swept wing with the smallest AR. These results indicate that, in a flapping forward flight, sweeping a forewing forward relative to a hindwing is suitable for cruising. The flow mechanisms and decoupled and coupled effects of the wing-swept angle and the AR presented in this paper provide insight into the flight of a butterfly and the design of a MAV.

8.
Pulm Circ ; 13(2): e12211, 2023 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-37007933

RESUMO

Approximately 25%-30% of patients diagnosed with idiopathic pulmonary arterial hypertension (PAH) have a clustered underlying Mendelian genetic cause and should be classified as heritable PAH (HPAH). The sixth World Symposium on Pulmonary Hypertension listed AQP1 as a PAH-related gene. AQP1 and its protein product Aquaporin-1 (AQP1) are found in abundance within pulmonary artery smooth muscle cells. Here, we report a family affected by HPAH with all three siblings carrying the same novel missense variant of AQP1 c.273C>G (p.Ile91Met). The youngest brother and the older sister both had dyspnea and edema and were diagnosed with HPAH about 10 years ago. In 2021, they received genetic tests that revealed all three siblings carried the same novel variant of AQP1 (c.273C>G). The brother in between these two siblings, although originally claimed to be asymptomatic, raised awareness. He then sought medical examination and confirmed the diagnosis of HPAH as well. This report on all three siblings carrying the same novel variant of AQP1 (c.273C>G) highlighted the importance of genetic testing and counseling for family members when PAH was first detected.

9.
Commun Biol ; 6(1): 267, 2023 03 14.
Artigo em Inglês | MEDLINE | ID: mdl-36918719

RESUMO

Genomic imprinting predominantly occurs in the placenta and brain. Few imprinted microRNAs have been identified in the brain, and their functional roles in the brain are not clear. Here we show paternal, but not maternal, expression of MIR125B2 in human but not mouse brain. Moreover, Mir125b-2m-/p- mice showed impaired learning and memory, and anxiety, whose functions were hippocampus-dependent. Hippocampal granule cells from Mir125b-2m-/p- mice displayed increased neuronal excitability, increased excitatory synaptic transmission, and decreased inhibitory synaptic transmission. Glutamate ionotropic receptor NMDA type subunit 2A (Grin2a), a key regulator of synaptic plasticity, was physically bound by miR-125b-2 and upregulated in the hippocampus of Mir125b-2m-/p- mice. Taken together, our findings demonstrate MIR125B2 imprinted in human but not mouse brain, mediated learning, memory, and anxiety, regulated excitability and synaptic transmission in hippocampal granule cells, and affected hippocampal expression of Grin2a. Our work provides functional mechanisms of a species-specific imprinted microRNA in the brain.


Assuntos
Hipocampo , MicroRNAs , Animais , Humanos , Camundongos , Hipocampo/metabolismo , MicroRNAs/genética , MicroRNAs/metabolismo , Plasticidade Neuronal/fisiologia , Neurônios/metabolismo , Transmissão Sináptica/fisiologia
10.
Front Cardiovasc Med ; 9: 911649, 2022.
Artigo em Inglês | MEDLINE | ID: mdl-35811711

RESUMO

Background: Genetic variants could be identified in subjects with idiopathic and heritable pulmonary arterial hypertension (PAH). The 6th World Symposium on Pulmonary Hypertension (WSPH) provided a list of genes with evidence of association with PAH. However, reports using whole exome sequencing (WES) from southeastern Asian PAH cohorts were scarce. Methods: Subjects with idiopathic and heritable PAH (N = 45) from two medical centers in central Taiwan were screened for PAH related gene variants. The genomic DNA was prepared from peripheral blood lymphocytes. We performed WES for all patients enrolled in this study. All identified gene variants were validated by polymerase-chain reaction and Sanger sequencing. The clinical and hemodynamic data were compared between bone morphogenetic protein receptor type-2 (BMPR2) gene variants carriers vs. non-carriers. Results: Eight patients (8/45 = 17.8%) was identified carrying BMPR2 gene variants and 8 patients (8/45 = 17.8%) had other WSPH-listed PAH-related gene variants (1 with ACVRL1, 1 with ENG, 1 with SMAD9, 1 with SMAD1, 1 with ATP13A3 and 3 with AQP1). In addition, a total of 14 non-WSPH-listed PAH-related genetic variant sites (ABCC8, NOTCH1, NOTCH2, NOTCH3, JAG1, BMP10, GGCX, FBLN2, ABCA3 and PTGIS) were found in this PAH cohort. Subjects carrying BMPR2 gene variant (N = 8) were younger at diagnosis of PAH (30 ± 11 vs 49 ± 13 years, p = 0.001) than the non-carrier group (N = 37). BMPR2 variant carriers had a trend toward having higher mean pulmonary arterial pressure (PAP) (61 ± 19 vs. 51 ± 13 mmHg, p = 0.076) than the non-carriers upon initial diagnosis. Pulmonary vascular resistance, right atrial pressure, cardiac output, as well as functional class were similar between BMPR2 variant carriers and non-carriers at initial diagnosis. Conclusions: We identified 17.8% of patients with BMPR2 gene variants and 17.8% subjects with other 6th WSPH-listed PAH-related gene variants in a Taiwanese idiopathic and heritable PAH cohort. PAH patients carrying BMPR2 variants presented at a younger age with a trend toward having higher mean PAP at initial diagnosis.

11.
Am J Cancer Res ; 12(10): 4764-4774, 2022.
Artigo em Inglês | MEDLINE | ID: mdl-36381326

RESUMO

MicroRNA (miRNA) expression is reportedly associated with clinical outcomes in childhood acute lymphoblastic leukemia (ALL). Here, we aimed at investigating whether miRNA expression is associated with clinical outcomes in pediatric ALL patients treated with the Taiwan Pediatric Oncology Group (TPOG) protocols. The expression of 397 miRNAs was measured using stem-loop quantitative real-time polymerase chain reaction miRNA arrays in 60 pediatric ALL patients treated with TPOG-ALL-93 or TPOG-ALL-97 VHR (very high-risk) protocols. In order to identify prognosis-related miRNAs, original cohort was randomly split into the training and testing cohort in a 2:1 ratio, and univariate Cox proportional hazards regression was applied to identify associations between event-free survival (EFS) and expressions of miRNAs. Four prognosis-related miRNAs were selected and validated in another independent cohort composed of 103 patients treated with the TPOG-ALL-2002 protocol. Risk score, including the impact of four prognosis-related miRNAs, was calculated for each patients, followed by grouping patients into the high or low risk-score groups. Irrespective of the training, testing, or validation cohort, risk-score group was significantly associated with EFS and overall survival (OS). Risk-score group combining with clinical characteristics including the age onset (≥10 years), white blood cell counts (≥100 × 109/L), cell type (T- or B-cell), sex, and risk groups of the treatment protocols were used as predictors of EFS using the multivariate Cox proportional hazards regression. Results showed that the risk-score group was the strongest predictor. In the validation cohort, hazard ratios (HRs) of the risk-score group were 7.06 (95% CI=1.93-25.84, p-value =0.003) and 14.03 (95% CI=3.34-59.04, p-value =0.003) for EFS and OS, respectively. High risk-score group had higher risk of having poor prognosis and risk of death than that in the low risk group. Accuracy of the prediction model for 5-year EFS could reach 0.76. For the prediction of 5-year OS, accuracy was 0.75. In conclusion, a miRNA signature was associated with clinical outcomes in childhood ALL patients treated with TPOG protocols and might be a suitable prognostic biomarker.

12.
R Soc Open Sci ; 8(8): 202172, 2021 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-34457326

RESUMO

Unlike other insects, a butterfly uses a small amplitude of the wing-pitch motion for flight. From an analysis of the dynamics of real flying butterflies, we show that the restrained amplitude of the wing-pitch motion enhances the wake-capture effect so as to enhance forward propulsion. A numerical simulation refined with experimental data shows that, for a small amplitude of the wing-pitch motion, the shed vortex generated in the downstroke induces air in the wake region to flow towards the wings. This condition enables a butterfly to capture an induced flow and to acquire an additional forward propulsion, which accounts for more than 47% of the thrust generation. When the amplitude of the wing-pitch motion exceeds 45°, the flow induced by the shed vortex drifts away from the wings; it attenuates the wake-capture effect and causes the butterfly to lose a part of its forward propulsion. Our results provide one essential aerodynamic feature for a butterfly to adopt a small amplitude of the wing-pitch motion to enhance the wake-capture effect and forward propulsion. This work clarifies the variation of the flow field correlated with the wing-pitch motion, which is useful in the design of wing kinematics of a micro-aerial vehicle.

13.
Sci Rep ; 11(1): 2377, 2021 01 27.
Artigo em Inglês | MEDLINE | ID: mdl-33504864

RESUMO

MicroRNA-125b, the first microRNA to be identified, is known to promote cardiomyocyte maturation from embryonic stem cells; however, its physiological role remains unclear. To investigate the role of miR-125b in cardiovascular biology, cardiac-specific miR-125b-1 knockout mice were generated. We found that cardiac-specific miR-125b-1 knockout mice displayed half the miR-125b expression of control mice resulting in a 60% perinatal death rate. However, the surviving mice developed hearts with cardiac hypertrophy. The cardiomyocytes in both neonatal and adult mice displayed abnormal mitochondrial morphology. In the deficient neonatal hearts, there was an increase in mitochondrial DNA, but total ATP production was reduced. In addition, both the respiratory complex proteins in mitochondria and mitochondrial transcription machinery were impaired. Mechanistically, using transcriptome and proteome analysis, we found that many proteins involved in fatty acid metabolism were significantly downregulated in miR-125b knockout mice which resulted in reduced fatty acid metabolism. Importantly, many of these proteins are expressed in the mitochondria. We conclude that miR-125b deficiency causes a high mortality rate in neonates and cardiac hypertrophy in adult mice. The dysregulation of fatty acid metabolism may be responsible for the cardiac defect in the miR-125b deficient mice.


Assuntos
Cardiomegalia/etiologia , Predisposição Genética para Doença , MicroRNAs/genética , Miócitos Cardíacos/metabolismo , Morte Perinatal/etiologia , Animais , Cardiomegalia/metabolismo , Cardiomegalia/patologia , Cardiomegalia/fisiopatologia , Biologia Computacional , Perfilação da Expressão Gênica , Regulação da Expressão Gênica , Marcação de Genes , Estudos de Associação Genética , Testes de Função Cardíaca , Humanos , Imuno-Histoquímica , Camundongos , Camundongos Knockout , Mitocôndrias Cardíacas/genética , Mitocôndrias Cardíacas/metabolismo , Especificidade de Órgãos/genética , Fenótipo , Proteômica/métodos , Interferência de RNA , Transcriptoma
14.
Pediatr Blood Cancer ; 54(2): 206-11, 2010 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-19774638

RESUMO

OBJECTIVES: This retrospective study evaluates the role of pharmacogenomic determinants in the treatment of childhood acute lymphoblastic leukemia (ALL) in the Taiwanese population. METHODS: A total of 105 childhood ALL patients received combined chemotherapy of different intensities based on risk-directed Taiwan Pediatric Oncology Group (TPOG)-ALL-93 protocols. Seventeen genetic polymorphisms in 13 pharmacogenomic targets were analyzed by PCR-based restriction fragment length polymorphism (RFLP) and sequence-specific oligonucleotide (SSO) probe hybridization. Pharmacogenomic polymorphisms were correlated with event-free survival (EFS) of patients, with confounding effects adjusted by multivariate regression. RESULTS: Three polymorphic alleles in the multi-drug resistance 1 (MDR1) ABCB1 gene, and homozygotic MDR1 2677GG, 3435CC, and 2677G-3435C genotypes were highly associated with a significant reduction in EFS in those patients treated by the standard risk (SR) protocol (TPOG-ALL-93-SR). The hazard ratios were 6.8 (p = 0.01), 21.7 (p = 0.009), and 6.8 (p = 0.01), respectively. CONCLUSIONS: Independent pharmacogenomic determinants associated with treatment outcome were identified in subsets of Taiwanese ALL patients.


Assuntos
Membro 1 da Subfamília B de Cassetes de Ligação de ATP/genética , Protocolos de Quimioterapia Combinada Antineoplásica/farmacologia , Resistência a Medicamentos/genética , Polimorfismo Genético , Leucemia-Linfoma Linfoblástico de Células Precursoras/tratamento farmacológico , Leucemia-Linfoma Linfoblástico de Células Precursoras/genética , Povo Asiático/genética , Criança , Pré-Escolar , Feminino , Humanos , Lactente , Recém-Nascido , Masculino , Análise Multivariada , Farmacogenética , Modelos de Riscos Proporcionais , Estudos Retrospectivos , Análise de Sobrevida , Taiwan
15.
Bioinspir Biomim ; 16(1)2020 12 09.
Artigo em Inglês | MEDLINE | ID: mdl-33075754

RESUMO

We investigated the effect of the wing-wing interaction, which is one key aspect of flight control, of damselflies (Matrona cyanopteraandEuphaea formosa) in forward flight that relates closely to their body morphologies and wing kinematics. We used two high-speed cameras aligned orthogonally to measure the flight motions and adopted 3D numerical simulation to analyze the flow structures and aerodynamic efficiencies. The results clarify the effects of wing-wing interactions, which are complicated combinations of biological morphology, wing kinematics and fluid dynamics. As the amplitude of the hindwing ofM. cyanopterais larger than that ofE. formosa, the effect of the wing-wing interaction is more constructive. Restricted by the body morphology ofE. formosa, the flapping range of the hindwing is below the body. With the forewing in the lead, the hindwing is farther from the forewing, which is not susceptible to the wake of the forewing, and enables superior lift and thrust. Because of the varied rotational motions, the different shed direction of the wakes of the forewings causes the optimal thrust to occur in different wing phases. Because of its biological limitations, a damselfly can use an appropriate phase to fulfill the desired flight mode. The wing-wing interaction is a compromise between lift efficiency and thrust efficiency. The results reveal that a damselfly with the forewing in the lead can have an effective aerodynamic performance in flight. As an application, in the design concept of a micro-aircraft, increasing the amplitude of the hindwing might enhance the wing-wing interaction, thus controlling the flight modes.


Assuntos
Odonatos , Animais , Fenômenos Biomecânicos , Simulação por Computador , Voo Animal , Modelos Biológicos , Asas de Animais
16.
Phys Rev E ; 102(6-1): 062407, 2020 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-33466078

RESUMO

Butterflies fly with an abdomen oscillating relative to the thorax; the abdominal oscillation causes body parts to undulate translationally relative to the center of mass of a butterfly, which could generate a significant effect on flight. Based on experimental measurements, we created a numerical model to investigate this effect in a free-flying butterfly (Idea leuconoe). We fixed the motions of wing-flapping and thorax-pitching, and parametrized the abdominal oscillation by varied oscillating phase. To concentrate the analysis on translational dynamics, we used a motion of a thorax-abdomen node, a joint that the thorax and the abdomen rotate about, to express the translational motion of body parts relative to the center of mass. The results show that the abdominal oscillation enhances lift and thrust via the translational motion of the thorax-abdomen node relative to the center of mass. With the abdominal oscillating phase recorded from real butterflies, the abdominal oscillation causes the thorax-abdomen node to move downward relative to the center of mass in downstroke and move upward relative to the center of mass in upstroke. This constructive movement amplifies the wing-flapping speed relative to the center of mass, which enhances the angle of attack and the strength of leading- and trailing-edge vortices on the wings. The wings thereby generate increased values of instantaneous lift and thrust by 50.32% and 32.57% compared to the case of no abdominal oscillation. Natural butterflies are stated to utilize a particular phase offset of abdominal oscillation to fly. With comparing varied oscillating phases, only the abdominal oscillating phase recorded from natural butterflies produces the best constructive effect on the translational motion of thorax-abdomen node, which maximizes the lift and thrust generated on the wings. It clarifies that butterflies use this specific range of abdominal oscillating phase to regulate the translational motion between the thorax-abdomen node and the center of mass to enhance flight. Our work reveals the translational mechanism of the abdominal oscillation, which is as important as the thorax-pitching effect. The findings in this work provide insight into the flight of butterflies and the design of micro aerial vehicles.


Assuntos
Abdome/fisiologia , Borboletas , Modelos Biológicos , Tórax/fisiologia , Animais , Fenômenos Biomecânicos , Voo Animal , Asas de Animais
17.
Mol Genet Metab Rep ; 25: 100652, 2020 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-33101978

RESUMO

OBJECTIVE: To provide strategies for monitoring and treating severe lung involvement in Gaucher disease. STUDY DESIGN: We reviewed the chart of a 5-year-old boy who developed rapidly progressive, severe infiltrative lung involvement of Gaucher disease (GD) and improved after allogeneic hematopoietic stem cell transplant (HSCT), along with other case studies reported before December 2019. He was diagnosed with GD (homozygous mutation at c.1448 T > C, p.L483P), and started receiving enzyme replacement therapy (ERT) at 17 months old. He developed respiratory distress symptoms after 45 months of ERT; chest imaging reported diffuse interstitial infiltration of the bilateral lungs and consolidations at the right lungs. Allogeneic HSCT using cells from a matched unrelated donor was performed four months upon progressive respiratory symptoms. RESULTS: His respiratory symptoms subsided in one month; chest imaging improvement, pulmonary function test improvement, and normalized activity of ß-glucocerebrosidase were reported in three months. CONCLUSION: This is the first report of a patient who received early and regular ERT but developed severe infiltrative lung involvement and recovered after allogeneic HSCT. Based on study results, we suggest regular chest imaging, even for asymptomatic patients. For patients with severe lung involvement, rapid deterioration, and unresponsive to higher ERT dosages, allogeneic HSCT should be considered.

18.
Orphanet J Rare Dis ; 15(1): 337, 2020 12 01.
Artigo em Inglês | MEDLINE | ID: mdl-33256818

RESUMO

BACKGROUND: Glutaric aciduria type 1 (GA-1) is a rare disease connected with speech delay and neurological deficits. However, the audiological and otologic profiles of GA-1 have not yet been fully characterized. To our knowledge, this is the largest study of comprehensive audiological and otologic evaluation in patients with GA-1 to date. METHODS: Thirteen patients diagnosed with GA-1 between January 1994 and December 2019 with audiological, radiological and genetic manifestations were retrospectively analyzed. Hearing tests were performed in all patients. MRI was performed for radiological evaluation. RESULTS: Hearing loss was found in 76.9% (10/13) of GA-1 patients, including slight hearing loss in 46.1% (6/13) of patients, mild hearing loss in 15.4% (2/13) of patients, and moderate hearing loss in 7.7% (1/13) of patients. Normal hearing thresholds were seen in 23% (3/13) of patients. Patients with intensive care unit (ICU) admission history showed significantly worse hearing than those without (29.17 ± 12.47 vs 13.56 ± 3.93 dB HL, 95% CI 2.92-24.70, p = 0.0176). One patient had moderate sensorineural hearing loss and a past history of acute encephalopathic crisis. No usual causative gene mutations associated with hearing loss were found in these patients. MRI showed a normal vestibulocochlear apparatus and cochlear nerve. One patient with extensive injury of the basal ganglia on MRI after acute encephalopathic crisis was found to have moderate sensorineural hearing loss. Two patients with disability scores above 5 were found to have mild to moderate hearing impairment. No obvious correlation between macrocephaly and hearing loss was found. CONCLUSION: A high prevalence of hearing impairment is found in GA-1 patients. Adequate audiological evaluation is essential for these patients, especially for those after encephalopathic crises or with ICU admission history.


Assuntos
Erros Inatos do Metabolismo dos Aminoácidos , Encefalopatias Metabólicas , Perda Auditiva Neurossensorial , Glutaril-CoA Desidrogenase/deficiência , Glutaril-CoA Desidrogenase/genética , Perda Auditiva Neurossensorial/genética , Humanos , Estudos Retrospectivos
19.
J Am Coll Cardiol ; 68(23): 2554-2563, 2016 Dec 13.
Artigo em Inglês | MEDLINE | ID: mdl-27931613

RESUMO

BACKGROUND: Recently, several studies revealed a much higher prevalence of later onset Fabry disease (FD) than previously expected. It suggested that later onset FD might present as an important hidden health issue in certain ethnic or demographic populations in the world. However, the natural history of its phenotype has not been systemically investigated, especially the cardiac involvement. OBJECTIVES: The study analyzed a large-scale newborn screening program for FD to understand the natural course of later onset FD. METHODS: To date, 916,383 newborns have been screened for FD in Taiwan, including more than 1,200 individuals with the common, later onset IVS4+919G>A (IVS4) mutation. Echocardiography was performed in 620 adults with the IVS4 mutation to analyze the prevalence of left ventricular hypertrophy (LVH), and gadolinium-enhanced cardiac magnetic resonance imaging was performed in 129 patients with FD, including 100 IVS4 adults. RESULTS: LVH was observed in 67% of men and 32% of women older than 40 years. Imaging evidenced significant late gadolinium enhancement in 38.1% of IVS4 men and 16.7% of IVS4 women with the IVS4 mutation but without LVH. Seventeen patients underwent endomyocardial biopsies, which revealed significant globotriaosylceramide substrate accumulation in their cardiomyocytes. CONCLUSIONS: Significant cardiomyocyte substrate accumulation in IVS4 patients led to severe and irreversible cardiac fibrosis before development of LVH or other significant cardiac manifestations. Thus, it might be too late to start enzyme replacement therapy after the occurrence of LVH or other significant cardiac manifestations in patients with later onset FD. This study also indicated the importance of newborn screening for early detection of the insidious, ongoing, irreversible cardiac damage in patients with later onset FD.


Assuntos
Doença de Fabry/epidemiologia , Hipertrofia Ventricular Esquerda/etiologia , Mutação , Triagem Neonatal/métodos , alfa-Galactosidase/genética , Adulto , Idade de Início , Idoso , Idoso de 80 Anos ou mais , Análise Mutacional de DNA , Ecocardiografia , Doença de Fabry/complicações , Doença de Fabry/genética , Feminino , Humanos , Hipertrofia Ventricular Esquerda/diagnóstico , Recém-Nascido , Masculino , Pessoa de Meia-Idade , Fenótipo , Prevalência , Estudos Retrospectivos , Taiwan/epidemiologia , Adulto Jovem , alfa-Galactosidase/metabolismo
20.
Nanoscale ; 7(2): 776-83, 2015 Jan 14.
Artigo em Inglês | MEDLINE | ID: mdl-25431303

RESUMO

The organic polymer solar cell is recognized as one of the most competitive technologies of the next generation. Au nanoparticles and ZnO nanorods were combined to improve the inverted-structure low-bandgap polymer solar cells and enhance the absorption and efficiency of the devices. However, the Au nanoparticles tend to aggregate in solution, thus reducing the localized surface plasmon resonance (LSPR) effect. The cluster effect on the spectral range of enhancement in the absorption is investigated and the absorption characteristics of the LSPR receive proper modification through our experiment. After reducing the number of Au nanoparticle clusters, the LSPR effect in the devices was clearly verified. The proper combination of the Au nanoparticles and ZnO nanorods leads to the power conversion efficiency of the PTB7 : PC71BM inverted organic solar cell reaching 8.04% after optimizing the process conditions.

SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA